CLOs on the Move

Curran Biotech

www.curranbiotech.com

 
Curran Biotech is a materials manufacturing company that provides nano coatings to biochemical, chemical, energy and construction industries including water-repellent coatings for fabrics, canvas, tarps, and glass. Our hydrophobic coatings are specifically designed to improve the nature and quality of the substrates by preventing water-substrate interactions. The technology was developed in the materials/chemistry labs (Institute for Nano Energy) of the physics department at the University of Houston and started commercialization in 2013.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.curranbiotech.com
  • 5000 Gulf Freeway Building 5, Room No 120/122
    Houston, TX USA 77023
  • Phone: 832.671.6647

Executives

Name Title Contact Details

Similar Companies

Treasure Coast Radiation Oncology, Pa

Treasure Coast Radiation Oncology, Pa is a Stuart, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Miroculus

Miroculus Miro Canvas platform can automate complex protocols, such as NGS library prep, in a compact, cartridge-based system that is within reach of all laboratories. Miroculus makes science easy and accessible. By putting intuitive tools in the hands of people everywhere, we can advance science and improve lives faster, together.

Limelight Bio

Limelight is a privately held, multi-platform, multi-disease biopharmaceutical company headquartered in Philadelphia, PA and Cambridge, MA

Abpro

We are a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.